UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 8, 2005
--------------------------------
Molecular Diagnostics, Inc.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
Delaware 0-935 36-4296006
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
414 North Orleans Street, Suite 502, Chicago, Illinois 60610
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (312) 222-9550
-----------------------------
Not Applicable
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
FORM 8-K
Item Page
- ---- ----
Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers 1
Item 9.01 Financial Statements and Exhibits 1
Signature 1
Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers
On September 8, 2005, Robert McCullough, Jr. accepted the nomination of
the Board of Directors to become a director of the Company. The Board had
nominated Mr. McCullough on August 29, 2005, to become effective upon Mr.
McCullough's acceptance. Any committee appointments will be announced upon board
approval.
Mr. McCullough has an MBA in finance and is a Certified Public Accountant.
He was an executive at Ernst & Young (formerly Ernst & Whinney), and served as
CFO at two privately-owned health care companies. Mr. McCullough has been in the
investment business for the last 18 years as a Portfolio Manager/Security
Analyst, and currently as President of Summitcrest Capital Management. Mr.
McCullough has been an investor in Molecular Diagnostics since 2001.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release dated September 8, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Molecular Diagnostics, Inc.
Dated: September 8, 2005 By: /s/ David Weissberg, M.D.
--------------------------------
David Weissberg, M.D.
Chief Executive Officer